Literature DB >> 23104048

Sorrell v. IMS Health: issues and opportunities for informaticians.

Carolyn Petersen1, Paul Demuro, Kenneth W Goodman, Bonnie Kaplan.   

Abstract

In 2011, the US Supreme Court decided Sorrell v. IMS Health, Inc., a case that addressed the mining of large aggregated databases and the sale of prescriber data for marketing prescription drugs. The court struck down a Vermont law that required data mining companies to obtain permission from individual providers before selling prescription records that included identifiable physician prescription information to pharmaceutical companies for drug marketing. The decision was based on constitutional free speech protections rather than data sharing considerations. Sorrell illustrates challenges at the intersection of biomedical informatics, public health, constitutional liberties, and ethics. As states, courts, regulatory agencies, and federal bodies respond to Sorrell, informaticians' expertise can contribute to more informed, ethical, and appropriate policies.

Mesh:

Year:  2012        PMID: 23104048      PMCID: PMC3555336          DOI: 10.1136/amiajnl-2012-001123

Source DB:  PubMed          Journal:  J Am Med Inform Assoc        ISSN: 1067-5027            Impact factor:   4.497


  20 in total

1.  Physicians and the pharmaceutical industry: is a gift ever just a gift?

Authors:  A Wazana
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

2.  Marketing pharmaceuticals: a constitutional right to sell prescriber-identified data?

Authors:  Lawrence O Gostin
Journal:  JAMA       Date:  2012-02-22       Impact factor: 56.272

3.  All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving.

Authors:  Dana Katz; Arthur L Caplan; Jon F Merz
Journal:  Am J Bioeth       Date:  2010-10       Impact factor: 11.229

4.  COX-2 inhibitors--a lesson in unexpected problems.

Authors:  Jeffrey M Drazen
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

5.  Data-mining case tests boundaries of medical privacy.

Authors:  Cal Woodward
Journal:  CMAJ       Date:  2011-04-26       Impact factor: 8.262

6.  Higher First Amendment hurdles for public health regulation.

Authors:  Kevin Outterson
Journal:  N Engl J Med       Date:  2011-08-03       Impact factor: 91.245

7.  Restrictions on the use of prescribing data for drug promotion.

Authors:  Michelle M Mello; Noah A Messing
Journal:  N Engl J Med       Date:  2011-08-03       Impact factor: 91.245

8.  Physicians, pharmaceutical sales representatives, and the cost of prescribing.

Authors:  T S Caudill; M S Johnson; E C Rich; W P McKinney
Journal:  Arch Fam Med       Date:  1996-04

9.  Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone.

Authors:  Julie J Wilkinson; Rex W Force; Paul S Cady
Journal:  Pharmacotherapy       Date:  2004-08       Impact factor: 4.705

10.  Economic implications of evidence-based prescribing for hypertension: can better care cost less?

Authors:  Michael A Fischer; Jerry Avorn
Journal:  JAMA       Date:  2004-04-21       Impact factor: 56.272

View more
  2 in total

1.  The role of law in supporting secondary uses of electronic health information.

Authors:  Tara Ramanathan; Cason Schmit; Akshara Menon; Chanelle Fox
Journal:  J Law Med Ethics       Date:  2015       Impact factor: 1.718

2.  Biomedical data privacy: problems, perspectives, and recent advances.

Authors:  Bradley A Malin; Khaled El Emam; Christine M O'Keefe
Journal:  J Am Med Inform Assoc       Date:  2012-12-06       Impact factor: 4.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.